Oct 02, 2024 8:00 am EDT Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats
Sep 30, 2024 8:00 am EDT Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
Sep 12, 2024 8:00 am EDT Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act
Sep 09, 2024 8:30 am EDT Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
Aug 26, 2024 8:00 am EDT Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow
Aug 20, 2024 9:15 am EDT Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
Aug 09, 2024 3:38 pm EDT Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering
Aug 06, 2024 8:45 am EDT Scorpius Holdings Weighted-Average Pipeline Surpasses $100 Million in Business Develop Opportunities Across Both Manufacturing Client and Government Sectors